REGENXBIO Inc. (NASDAQ:RGNX) CFO Vittal Vasista sold 5,000 shares of REGENXBIO stock in a transaction on Monday, October 16th. The stock was sold at an average price of $33.25, for a total transaction of $166,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Vittal Vasista also recently made the following trade(s):

  • On Friday, September 15th, Vittal Vasista sold 5,000 shares of REGENXBIO stock. The stock was sold at an average price of $27.39, for a total transaction of $136,950.00.
  • On Tuesday, August 15th, Vittal Vasista sold 3,040 shares of REGENXBIO stock. The stock was sold at an average price of $21.09, for a total transaction of $64,113.60.

Shares of REGENXBIO Inc. (RGNX) traded up 2.66% on Wednesday, reaching $32.85. 202,659 shares of the company’s stock were exchanged. The company’s 50 day moving average is $30.68 and its 200-day moving average is $30.68. REGENXBIO Inc. has a one year low of $15.25 and a one year high of $36.10. The stock’s market cap is $1.01 billion.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.34. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. The business had revenue of $6.56 million for the quarter. On average, analysts anticipate that REGENXBIO Inc. will post ($2.93) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/18/vittal-vasista-sells-5000-shares-of-regenxbio-inc-rgnx-stock.html.

A number of hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its stake in REGENXBIO by 1.1% in the second quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock worth $320,000 after purchasing an additional 175 shares during the period. People s United Financial Inc. increased its stake in REGENXBIO by 3.4% in the second quarter. People s United Financial Inc. now owns 17,150 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 560 shares during the period. Bank of America Corp DE increased its stake in REGENXBIO by 1.2% in the first quarter. Bank of America Corp DE now owns 51,380 shares of the biotechnology company’s stock worth $992,000 after purchasing an additional 597 shares during the period. American International Group Inc. increased its stake in REGENXBIO by 7.1% in the first quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 822 shares during the period. Finally, Asymmetry Capital Management L.P. increased its stake in REGENXBIO by 12.2% in the second quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 1,508 shares during the period. Institutional investors and hedge funds own 73.26% of the company’s stock.

RGNX has been the topic of several analyst reports. Raymond James Financial, Inc. initiated coverage on shares of REGENXBIO in a research note on Thursday, October 12th. They issued an “outperform” rating and a $39.00 target price on the stock. Bank of America Corporation reaffirmed a “buy” rating and issued a $38.00 target price (up from $33.00) on shares of REGENXBIO in a research note on Monday, October 9th. Chardan Capital reaffirmed a “buy” rating and issued a $75.00 target price (up from $55.00) on shares of REGENXBIO in a research note on Tuesday, September 5th. Zacks Investment Research downgraded shares of REGENXBIO from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Finally, Evercore ISI initiated coverage on shares of REGENXBIO in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $40.00.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Insider Buying and Selling by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Stock Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related stocks with our FREE daily email newsletter.